Quick Answer
Century Therapeutics, Inc. reported Revenue (ASC 606) of $109.16 million for fiscal year 2025.
Century Therapeutics, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $109.16M | +1556.8% |
| 2024 | $6.59M | +194.8% |
| 2023 | $2.23M | -57.0% |
| 2022 | $5.20M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| March 31, 2025 | $109.16M | +12667.7% | +13700.8% |
| September 30, 2024 | $791.0K | +434.5% | +2.6% |
| June 30, 2024 | $771.0K | +678.8% | -9.8% |
| March 31, 2024 | $855.0K | -50.3% | +477.7% |
| September 30, 2023 | $148.0K | -93.3% | +49.5% |
| June 30, 2023 | $99.0K | -92.9% | -94.2% |
| March 31, 2023 | $1.72M | +62.6% | -22.7% |
| September 30, 2022 | $2.22M | — | +59.3% |
- Century Therapeutics, Inc. showed an increase of +1556.8% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2022–2025 period, Century Therapeutics, Inc.’s revenue (asc 606) has grown by 1999.7% (from $5.20 million to $109.16 million).
- The most recent figure is from Century Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: